New evidence of anti-inflammatory interventions in atrial fibrillation: reply

被引：4

作者：

Boos, CJ ^{[1
]}

Lip, GYH ^{[1
]}

机构：

[1] City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England

来源：

EUROPEAN HEART JOURNAL | 2006年 / 27卷 / 04期

关键词：

D O I：

10.1093/eurheartj

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：501 / 501

页数：1

共 7 条

[1]

CHERUKU KK, 2004, PREV CARDIOL, V7, P11

[2]

Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress:: implications for β-blocker selection [J].

Chin, BSP ;

Gibbs, CR ;

Blann, AD ;

Lip, GYH .

CLINICAL SCIENCE, 2003, 105 (04) :507-512

[3]

Effect of C-reactive protein reduction on paroxysmal atrial fibrillation [J].

Dernellis, J ;

Panaretou, M .

AMERICAN HEART JOURNAL, 2005, 150 (05) :1064.e7-1064.e12

[4]

Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting [J].

Marín, F ;

Pascual, DA ;

Roldán, V ;

Arribas, JM ;

Ahumada, M ;

Tornel, PL ;

Oliver, C ;

Gómez-Plana, J ;

Lip, GYH ;

Valdés, M .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (01) :55-60

[5]

Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation [J].

Merritt, JC ;

Niebauer, M ;

Tarakji, K ;

Hammer, D ;

Mills, RM .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) :735-736

[6]

Schwartz GG, 2004, CIRCULATION, V110, P740

[7]

*STOP AF, NCT00252967 STOPAF

← 1 →